Загрузка...
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF–expressing tumor cells
BACKGROUND: Glioma immunotherapy is an active area of clinical investigation. Glioma-associated immunosuppression remains an obstacle to efficacious immunotherapy, and combination approaches are likely necessary for durable success. OX40 is a member of the tumor necrosis factor receptor superfamily...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5761505/ https://ncbi.nlm.nih.gov/pubmed/29016879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox125 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|